Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
144.00K | 0.00 | 0.00 | 0.00 | 2.01M | 6.56M | Gross Profit |
4.00K | -15.17M | -241.60K | -239.50K | 1.78M | 6.56M | EBIT |
-20.31M | -18.56M | -38.83M | -14.22M | -9.59M | -48.41M | EBITDA |
-18.95M | -19.37M | -38.45M | -13.80M | -9.30M | -47.90M | Net Income Common Stockholders |
-18.70M | -17.98M | -38.84M | -14.19M | -9.66M | -48.19M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
36.49K | 26.35M | 37.14M | 58.70M | 33.01M | 7.42M | Total Assets |
104.70K | 31.26M | 40.84M | 79.39M | 54.24M | 28.53M | Total Debt |
0.00 | 1.85M | 297.00K | 534.00K | 596.00K | 817.00K | Net Debt |
-36.49K | -24.50M | -36.85M | -58.17M | -32.41M | -6.60M | Total Liabilities |
53.31K | 4.88M | 1.27M | 1.84M | 1.74M | 2.82M | Stockholders Equity |
54.23K | 26.38M | 39.57M | 77.55M | 52.51M | 25.71M |
Cash Flow | Free Cash Flow | ||||
-11.74M | -14.78M | -21.51M | -12.77M | -10.07M | -1.71M | Operating Cash Flow |
-16.19M | -14.67M | -21.43M | -12.72M | -9.83M | -1.56M | Investing Cash Flow |
-57.01K | -118.00K | -74.00K | -52.00K | -240.00K | -145.00K | Financing Cash Flow |
-174.37K | 3.99M | -27.00K | 38.47M | 35.66M | 6.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $372.90M | 6.34 | 28.70% | 11.49% | -0.86% | -13.33% | |
75 Outperform | $140.11B | 293.83 | 2.28% | 2.76% | 6.16% | -91.54% | |
52 Neutral | $1.53B | ― | 18.68% | ― | 36.00% | 63.50% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
48 Neutral | $9.93B | ― | -28.77% | ― | -52.75% | 25.00% | |
39 Underperform | $900.73M | ― | 30.06% | ― | -30.65% | 77.62% | |
33 Underperform | $14.35M | ― | -97.50% | ― | ― | 9.46% |
Cocrystal Pharma, Inc. is presenting to the investment community on January 13, 2025, but the information shared in this presentation is not considered ‘filed’ under the Securities Exchange Act of 1934. This implies that while the company is engaging with investors, the details are not formally submitted for regulatory scrutiny, potentially limiting liability exposure.
Cocrystal Pharma announced positive interim results from a Phase 1 study of its oral pan-viral protease inhibitor CDI-988, designed for the treatment of norovirus and coronavirus infections. The study demonstrated favorable safety and tolerability at doses up to 800 mg for 10 days, supporting further development and clinical trials. With norovirus outbreaks rising significantly, the potential of CDI-988 to address this unmet need could strengthen Cocrystal’s position in the antiviral market, as the company plans to commence a human challenge study in 2025.